Let’s not use the eteplirsen approval as a way to lobby for new ways to put constraints on the biopharmaceutical industry.
John LaMattina, Contributor, Forbes
Wed, 10/26/2016 - 5:09am
Let’s not use the eteplirsen approval as a way to lobby for new ways to put constraints on the biopharmaceutical industry.